Takeuchi, Masashi
Yokose, Takahiro
Kawakubo, Hirofumi
Matsuda, Satoru
Mayanagi, Shuhei
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Wada, Norihito
Obara, Hideaki
Kitagawa, Yuko
Funding for this research was provided by:
LSI Medience Corporation.
School of Medicine, Keio University
Article History
Received: 25 December 2019
Accepted: 28 March 2020
First Online: 17 April 2020
Compliance with ethical standards
:
: Study protocol was first approved by the Institutional Review Board of Keio University School of Medicine.
: Yuko Kitagawa received grant support from TAIHO PHARMACEUTICAL CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD., Yakult Honsha Co. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Merck Serono Co., Ltd., AsahiKASEI Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., SHIONOGI & CO., LTD. KAKEN PHARMACEUTICAL CO., LTD., Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., MEDICON INC., DAINIPPON SUMITOMO PHARMA Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Pfizer Japan Inc., ONO PHARMACEUTICAL CO., LTD., NIHON PHARMACEUTICAL CO., LTD., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Sanofi K.K., grants from Eisai Co., Ltd. TSUMURA & CO., KCI Licensing, Inc., ABBOTT JAPAN CO., LTD., FUJIFILM Toyama Chemical Co., Ltd.